

UT Southwestern Medical Center

TAMEST COVID-19 Webinar

Mamta K. Jain, MD, MPH, FIDSA

June 11, 2020

Therapeutic Targets



Updated approaches against SARS-CoV-2. Li et. al. AAC Accepted Manuscript Posted Online 23 March 2020. Antimicrob. Agents Chemother. doi:10.1128/AAC.00483-20

Clinical Trials: UT Southwestern & PHHS

Gilead: remdesivir		**Regeneron: sarilumab**	**HERO: hydroxychloroquine**	**NIH ACTT2: remdesivir +/- baricitinib**
Moderate ; hospitalized	Severe; hospitalized	Severe to critical ; hospitalized	Prevention ; outpatient	Hospitalized
Inclusion : • + COVID ≤ 4 days • SpO2 >94% on room air • Pulmonary infiltrates	Inclusion : • + COVID ≤ 4 days • SpO2 ≤94% on room air or requiring supplemental oxygen • Pulmonary infiltrates	Inclusion: • +COVID pcr+ <14 days • Pulmonary infiltrates • Fever • Supplemental oxygen	Inclusion: • Healthcare workers with high risk exposure • Asymptomatic	Inclusion: • COVID pcr + <72 hours • Illness any duration with • No participation in other COVID-19 trials
Exclusion: • Participation in other COVID-19 trials • ALT or AST >5X ULN • Cr Cl <50 ml/min • Pregnancy/breastfeeding • Treatment with other COVID-19 antivirals < 24 hours • Mechanical ventilation	Exclusion: • Participation in other COVID-19 trials • ALT or AST >5X ULN • Cr Cl <50 ml/min • Pregnancy/breastfeeding • Treatment with other COVID-19 antivirals < 24 hours • Mechanical ventilation > 5 days	Exclusion: • ANC <2000mm^3 • AST or ALT >5 XULN • Platelet <50,000 per mm^3 • Receipt of leflunomide or methotrexate • Known active TB, extrapulmonary TB, suspected or active bacterial or fungal infection	Exclusion: • Symptoms of fever, cough, fever, shortness of breath for 5 days • Congenital prolonged qTC • use of medication which can lead to prolonged qTC • Prior COVID infection • End stage renal disease • Prior retinopathy	Exclusion: • Cr cl <30 ml/min • ALT or AST >5 ULN • Pregnancy/breastfeeding • Immunosuppressive medications • Live vaccine in prior 4 weeks • Active or untreated TB • Hx of VTE
Group 1 : 5 days Group 2: 10 days Group 3: standard of care	Group 1: 5 days Group 2: 10 days	Phase 2: Phase 3: Group 1: 200 mg. Cohort 1: 400 mg Group 2: 400 mg. Cohort 2: 800 mg Group 3: placebo Cohort 3: 800 mg	hydroxychloroquine 30 days vs placebo	remdesivir vs. remdesivir +baricitinib
Enrolled 25 patients	Enrolled: 135	Enrolled: 36	Enrolled: 12	Enrolled: 7
Closed	Closed	Open	Open	Open

Challenges of Clinical Trials During a Pandemic

- (1) Lack of knowledge of why we need to do clinical trials
  - I want a drug that works
  - I don’t want to be a “guinea pig”
  - I am afraid of the side effects
- (2) Is it ethical to give a placebo?
- (3)Infrastructure to scale up clinical trials
  - Research coordinators, data collection and entry, monitoring and reporting
- (3) Language barriers
- (4) consenting and working remotely
  - Lack of PPE, fear among research staff to see COVID-19 patients





Repurposed Drugs for COVID-19





Figure 2. Cumulative Incidence of Illness Compatible with Coronavirus Disease (Covid-19).





Cao B. et al, NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_home
Hung et al. *Lancet 2020* https://doi.org/10.1016/S0140-6736(20)31042-4
Beigel et al. *New Engl J Med* May 22, 2002
Boulware et al. *N Engl J Med* June 3, 2020